{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:56:01Z","timestamp":1781510161941,"version":"3.54.1"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82300247"],"award-info":[{"award-number":["82300247"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Translational Oncology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.tranon.2026.102706","type":"journal-article","created":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T16:52:26Z","timestamp":1771001546000},"page":"102706","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A review of treatment strategies for elderly patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"66","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-0856-1378","authenticated-orcid":false,"given":"Kaihang","family":"Shi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaoxiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5176-8472","authenticated-orcid":false,"given":"Xueyan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tranon.2026.102706_bib0001","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1612702","article-title":"The Global Burden of Leukemia and Its Attributable Factors in 204 Countries and Territories: findings from the Global Burden of Disease 2019 Study and Projections to 2030","volume":"2022","author":"Du","year":"2022","journal-title":"J. Oncol."},{"key":"10.1016\/j.tranon.2026.102706_bib0002","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.3324\/haematol.2021.279177","article-title":"Genetic and genomic analysis of acute lymphoblastic leukemia in older adults reveals a distinct profile of abnormalities: analysis of 210 patients from the UKALL14 and UKALL60+ clinical trials","volume":"107","author":"Creasey","year":"2022","journal-title":"Haematologica"},{"key":"10.1016\/j.tranon.2026.102706_bib0003","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2014.59.1636","article-title":"Childhood acute lymphoblastic leukemia: progress through collaboration","volume":"33","author":"Pui","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102706_bib0004","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1002\/cncr.23819","article-title":"Results of the hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen in elderly patients with acute lymphocytic leukemia","volume":"113","author":"O'Brien","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2026.102706_bib0005","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/j.1365-2141.2012.09095.x","article-title":"Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII\/ECOG2993 trial","volume":"157","author":"Sive","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tranon.2026.102706_bib0006","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1182\/blood-2016-11-749507","article-title":"Overall survival among older US adults with ALL remains low despite modest improvement since 1980: SEER analysis","volume":"129","author":"Geyer","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102706_bib0007","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood-2018-99-111954","article-title":"Comorbidities are frequent in older patients with de novo acute lymphoblastic leukemia (ALL) and correlate with induction mortality: analysis of more than 1200 patients from GMALL Data Bases","volume":"132","author":"Wermann","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102706_bib0008","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14737167.2018.1490645","article-title":"Economic burden associated with adverse events of special interest in patients with relapsed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the United States","volume":"18","author":"Zhang","year":"2018","journal-title":"Expert. Rev. Pharmacoecon. Outcomes. Res."},{"key":"10.1016\/j.tranon.2026.102706_bib0009","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23105515","article-title":"Neurotoxicity associated with treatment of acute lymphoblastic leukemia chemotherapy and immunotherapy","volume":"23","author":"\u015aliwa-Tytko","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tranon.2026.102706_bib0010","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/ajh.27708","article-title":"Adult acute lymphoblastic leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"100","author":"Kantarjian","year":"2025","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tranon.2026.102706_bib0011","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","article-title":"Pediatric acute lymphoblastic leukemia","volume":"105","author":"Inaba","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.tranon.2026.102706_bib0012","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of Haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.102706_bib0013","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.semdp.2023.10.001","article-title":"Updates on lymphoblastic leukemia\/lymphoma classification and minimal\/measurable residual disease analysis","volume":"40","author":"Kovach","year":"2023","journal-title":"Semin. Diagn. Pathol."},{"key":"10.1016\/j.tranon.2026.102706_bib0014","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1053\/j.semdp.2023.04.003","article-title":"Emerging molecular subtypes and therapies in acute lymphoblastic leukemia","volume":"40","author":"Davis","year":"2023","journal-title":"Semin. Diagn. Pathol."},{"key":"10.1016\/j.tranon.2026.102706_bib0015","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.clml.2017.02.009","article-title":"Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17 Abnormalities in B-Cell Acute Lymphoblastic Leukemia","volume":"17","author":"Khoral","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.tranon.2026.102706_bib0016","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1038\/s41408-025-01350-5","article-title":"Clinical and molecular characterization of TP53-mutant acute lymphoblastic leukemia in adults","volume":"15","author":"Harris","year":"2025","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.tranon.2026.102706_bib0017","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1182\/blood-2024-208340","article-title":"Age-Related Prognoses of Genetic Subtypes in B-Cell Acute Lymphoblastic Leukemia\/Lymphoma (B-ALL): insights from a Decade of National Data","volume":"144","author":"Zhou","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102706_bib0018","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/leu.2016.219","article-title":"Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial","volume":"31","author":"Patel","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.102706_bib0019","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1200\/JCO.24.00500","article-title":"Impact of Age on Pharmacogenomics and Treatment Outcomes of B-Cell Acute Lymphoblastic Leukemia","volume":"42","author":"Yoshimura","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102706_bib0020","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3324\/haematol.2014.118588","article-title":"Final report of a phase II study of imatinib mesylate with hyper-CVAD for the front-line treatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"100","author":"Daver","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.tranon.2026.102706_bib0021","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1600-0609.2006.00778.x","article-title":"Results of the PETHEMA ALL-96 trial in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia","volume":"78","author":"Sancho","year":"2007","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.tranon.2026.102706_bib0022","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/S2152-2650(20)30458-4","article-title":"Mini-hyper-CVD combinations for older adults: results of recent trials and a glimpse into the future","volume":"20","author":"Luskin","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.tranon.2026.102706_bib0023","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1200\/JCO.2009.26.9456","article-title":"Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia","volume":"28","author":"Thomas","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102706_bib0024","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1016\/S2352-3026(20)30144-7","article-title":"Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trial","volume":"7","author":"Jabbour","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.tranon.2026.102706_bib0025","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.pharmthera.2012.07.013","article-title":"Blinatumomab: a historical perspective","volume":"136","author":"Nagorsen","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.tranon.2026.102706_bib0026","doi-asserted-by":"crossref","first-page":"230.218","DOI":"10.4049\/jimmunol.210.Supp.230.18","article-title":"A novel tumor-bearing humanized mouse model for evaluating the efficacy and predictive safety of bispecific T cell engager","volume":"210","author":"Yang","year":"2023","journal-title":"J. Immunol."},{"key":"10.1016\/j.tranon.2026.102706_bib0027","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s11684-021-0835-8","article-title":"Preclinical characterization and comparison between CD3\/CD19 bispecific and novel CD3\/CD19\/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia","volume":"16","author":"Wang","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.tranon.2026.102706_bib0028","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1158\/1538-7445.AM2022-2077","article-title":"Abstract 2077: preclinical characterization of a next-generation CD19\/CD3-bispecific T cell engager with extended serum half-life and superior potency against CD19-low target cells","volume":"82","author":"Baeuerle","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.tranon.2026.102706_bib0029","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1182\/blood-2023-180472","article-title":"Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with Ph\/BCR::ABL Negative B-Precursor Adult Lymphoblastic Leukemia (ALL): preliminary Results of the GMALL Bold Trial","volume":"142","author":"Goekbuget","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102706_bib0030","doi-asserted-by":"crossref","first-page":"6134","DOI":"10.1182\/blood-2022-156080","volume":"140","author":"Jabbour","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102706_bib0031","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1002\/pbc.25410","article-title":"Characterization of CD22 expression in acute lymphoblastic leukemia","volume":"62","author":"Shah","year":"2015","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.tranon.2026.102706_bib0032","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/leu.2011.206","article-title":"The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells","volume":"26","author":"de Vries","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.102706_bib0033","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.3109\/10428194.2011.559668","article-title":"Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases","volume":"52","author":"Raponi","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.tranon.2026.102706_bib0034","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.2147\/DDDT.S150317","article-title":"Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"12","author":"Yurkiewicz","year":"2018","journal-title":"Drug Devel Ther"},{"key":"10.1016\/j.tranon.2026.102706_bib0035","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1182\/blood-2003-07-2466","article-title":"Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies","volume":"103","author":"DiJoseph","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102706_bib0036","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1038\/sj.leu.2404866","article-title":"Therapeutic potential of CD22-specific antibody-targeted chemotherapy using inotuzumab ozogamicin (CMC-544) for the treatment of acute lymphoblastic leukemia","volume":"21","author":"Dijoseph","year":"2007","journal-title":"Leukemia"},{"key":"10.1016\/j.tranon.2026.102706_bib0037","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2024-198800","article-title":"EBF1 Activity Controls Leukemia Sensitivity to Inotuzumab Ozogamicin","volume":"144","author":"Escherich","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102706_bib0038","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.1182\/blood-2024-208185","article-title":"PAX5 Loss Compromises CD22 Protein Levels and Responses to Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia","volume":"144","author":"Davis","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102706_bib0039","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/S1470-2045(18)30011-1","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukaemia: a single-arm, phase 2 study","volume":"19","author":"Kantarjian","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.tranon.2026.102706_bib0040","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1200\/JCO.24.00490","article-title":"Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22(+) Philadelphia Chromosome-Negative B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"42","author":"Chevallier","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102706_bib0041","doi-asserted-by":"crossref","first-page":"e433","DOI":"10.1016\/S2352-3026(23)00073-X","article-title":"Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial","volume":"10","author":"Jabbour","year":"2023","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.tranon.2026.102706_bib0042","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1002\/cncr.32139","volume":"125","author":"Jabbour","year":"2019","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2026.102706_bib0043","doi-asserted-by":"crossref","first-page":"331","DOI":"10.37349\/emed.2024.00223","article-title":"Dysregulation of BCL-2 family proteins in blood neoplasm: therapeutic relevance of antineoplastic agent venetoclax","volume":"5","author":"Tayeb","year":"2024","journal-title":"Explor. Med."},{"key":"10.1016\/j.tranon.2026.102706_bib0044","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00204-014-1448-7","article-title":"The mystery of BCL2 family: bcl-2 proteins and apoptosis: an update","volume":"89","author":"Siddiqui","year":"2015","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.tranon.2026.102706_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/hematology.2020000154","article-title":"Therapeutic development and current uses of BCL-2 inhibition","volume":"2020","author":"Roberts","year":"2020","journal-title":"Hematol. Am Soc Hematol Educ Program"},{"key":"10.1016\/j.tranon.2026.102706_bib0046","article-title":"BCL-2 inhibitors in hematological malignancies: biomarkers that predict response and management strategies","volume":"14","author":"Markouli","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tranon.2026.102706_bib0047","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1038\/s41388-022-02196-y","article-title":"Potent, p53-independent induction of NOXA sensitizes MLL-rearranged B-cell acute lymphoblastic leukemia cells to venetoclax","volume":"41","author":"Fidyt","year":"2022","journal-title":"Oncogene"},{"key":"10.1016\/j.tranon.2026.102706_bib0048","doi-asserted-by":"crossref","DOI":"10.1097\/01.HS9.0000968528.60716.f3","article-title":"P405: IN VITRO RESPONSE TO BCL-2 INHIBITION IN PEDIATRIC B PRECURSOR ALL WITH HIGH RISK CYTOGENETICS","volume":"7","author":"Gottardi","year":"2023","journal-title":"Hemasphere"},{"key":"10.1016\/j.tranon.2026.102706_bib0049","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1182\/bloodadvances.2024012906","article-title":"Blockage of BCL-XL overcomes venetoclax resistance across BCL2+ lymphoid malignancies irrespective of BIM status","volume":"8","author":"Dolnikova","year":"2024","journal-title":"Blood Adv."},{"key":"10.1016\/j.tranon.2026.102706_bib0050","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1182\/bloodadvances.2024014405","article-title":"Venetoclax plus low-intensity chemotherapy for adults with acute lymphoblastic leukemia","volume":"9","author":"Luskin","year":"2025","journal-title":"Blood Adv."},{"key":"10.1016\/j.tranon.2026.102706_bib0051","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1182\/blood-2023-174269","article-title":"Mini-Hyper-CVD plus venetoclax for treatment of older adults with newly diagnosed Ph-Negative B-ALL or T-ALL","volume":"142","author":"Luskin","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102706_bib0052","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.21.01766","article-title":"SWOG 1318: a Phase II trial of blinatumomab followed by POMP maintenance in older patients with newly diagnosed philadelphia chromosome-negative B-Cell acute lymphoblastic Leukemia","volume":"40","author":"Advani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102706_bib0053","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.23.00546","article-title":"Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL","volume":"42","author":"Stelljes","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102706_bib0054","doi-asserted-by":"crossref","first-page":"7006","DOI":"10.1200\/JCO.2023.41.16_suppl.7006","article-title":"Chemotherapy-free treatment with inotuzumab ozogamicin and blinatumomab for older adults with newly diagnosed, Ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: alliance A041703","volume":"41","author":"Wieduwilt","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.tranon.2026.102706_bib0055","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1182\/blood-2012-07-445098","article-title":"Allogeneic, but not autologous, hematopoietic cell transplantation improves survival only among younger adults with acute lymphoblastic leukemia in first remission: an individual patient data meta-analysis","volume":"121","author":"Gupta","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102706_bib0056","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1002\/cncr.30037","article-title":"Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia","volume":"122","author":"Fathi","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2026.102706_bib0057","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/ajh.24410","article-title":"Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission","volume":"91","author":"Wolach","year":"2016","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tranon.2026.102706_bib0058","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41409-024-02448-3","article-title":"Comparison of allo-SCT versus consolidation chemotherapy as post-remission therapy in acute lymphoblastic leukaemia aged \u226555 years","volume":"60","author":"Ma","year":"2025","journal-title":"Bone Marrow Transpl."},{"key":"10.1016\/j.tranon.2026.102706_bib0059","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tranon.2026.102706_bib0060","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1182\/blood-2006-05-018192","article-title":"Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12\/ECOG 2993 study","volume":"109","author":"Fielding","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102706_bib0061","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1002\/cncr.30031","article-title":"Blinatumomab treatment of older adults with relapsed\/refractory B-precursor acute lymphoblastic leukemia: results from 2 phase 2 studies","volume":"122","author":"Kantarjian","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2026.102706_bib0062","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1002\/cncr.31249","article-title":"Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATE","volume":"124","author":"Jabbour","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.tranon.2026.102706_bib0063","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.2169\/internalmedicine.4440-20","article-title":"Clinical Significance of Inotuzumab Ozogamicin in Non-transplant Patients with Relapsed Acute Lymphoblastic Leukemia: a Report of Four Cases","volume":"59","author":"Okura","year":"2020","journal-title":"Intern. Med."},{"key":"10.1016\/j.tranon.2026.102706_bib0064","doi-asserted-by":"crossref","DOI":"10.1177\/09636897241231892","article-title":"The progress and prospects of immune cell therapy for the treatment of cancer","volume":"33","author":"Han","year":"2024","journal-title":"Cell Transpl."},{"key":"10.1016\/j.tranon.2026.102706_bib0065","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1038\/mt.2009.83","article-title":"Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo","volume":"17","author":"Milone","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tranon.2026.102706_bib0066","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1177\/2040620715588916","article-title":"CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL)","volume":"6","author":"Tasian","year":"2015","journal-title":"Ther. Adv. Hematol."},{"key":"10.1016\/j.tranon.2026.102706_bib0067","doi-asserted-by":"crossref","unstructured":"Domizi P., Sarno J., Jager A., et al. IKAROS facilitates antigen escape in the face of CD19- and CD22-targeted therapies for B-cell acute lymphoblastic leukemia. bioRxiv 2024:2024.2011.2001.621347.","DOI":"10.1101\/2024.11.01.621347"},{"key":"10.1016\/j.tranon.2026.102706_bib0068","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.ymthe.2021.08.033","article-title":"A novel and efficient tandem CD19- and CD22-directed CAR for B cell ALL","volume":"30","author":"Zanetti","year":"2022","journal-title":"Mol. Ther."},{"key":"10.1016\/j.tranon.2026.102706_bib0069","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0140-6736(21)01222-8","article-title":"KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study","volume":"398","author":"Shah","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.tranon.2026.102706_bib0070","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13045-022-01379-0","article-title":"Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study","volume":"15","author":"Shah","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tranon.2026.102706_bib0071","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s11912-022-01272-6","article-title":"CAR T-Cell Therapy in the Older Person: indications and Risks","volume":"24","author":"Shouse","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.tranon.2026.102706_bib0072","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/s41591-018-0146-z","article-title":"Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia","volume":"24","author":"Orlando","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.tranon.2026.102706_bib0073","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the Antigen Density Requirement for CAR T-cell Activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.tranon.2026.102706_bib0074","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1182\/blood-2015-08-665547","article-title":"Acquisition of a CD19-negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T-cell therapy","volume":"127","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102706_bib0075","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1111\/bjh.19348","article-title":"The role of chimeric antigen receptor T cells targeting more than one antigen in the treatment of B-cell malignancies","volume":"204","author":"Brillembourg","year":"2024","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.tranon.2026.102706_bib0076","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1182\/blood.2019000017","article-title":"Efficacy and safety of CAR19\/22 T-cell cocktail therapy in patients with refractory\/relapsed B-cell malignancies","volume":"135","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102706_bib0077","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/ajh.26160","article-title":"Combination of CD19 and CD22 CAR-T cell therapy in relapsed B-cell acute lymphoblastic leukemia after allogeneic transplantation","volume":"96","author":"Liu","year":"2021","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.tranon.2026.102706_bib0078","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40164-022-00270-5","article-title":"A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed\/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy","volume":"11","author":"Zhang","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.tranon.2026.102706_bib0079","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1182\/blood.2023020621","article-title":"CD19\/CD22 targeting with cotransduced CAR T cells to prevent antigen-negative relapse after CAR T-cell therapy for B-cell ALL","volume":"143","author":"Ghorashian","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.tranon.2026.102706_bib0080","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1007\/s00277-020-04227-8","article-title":"Sequential therapy with inotuzumab ozogamicin, CD19 CAR T cells, and blinatumomab in an elderly patient with relapsed acute lymphoblastic leukemia","volume":"100","author":"Wullenkord","year":"2021","journal-title":"Ann. Hematol."}],"container-title":["Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326000434?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1936523326000434?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:47:56Z","timestamp":1781509676000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1936523326000434"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":80,"alternative-id":["S1936523326000434"],"URL":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102706","relation":{},"ISSN":["1936-5233"],"issn-type":[{"value":"1936-5233","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review of treatment strategies for elderly patients with Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Translational Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tranon.2026.102706","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102706"}}